ABO Rh Typing: Difference between revisions
Appearance
No edit summary |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
== ABO System == | |||
The ABO system is the most clinically significant blood group system in transfusion medicine. | The ABO system is the most clinically significant blood group system in transfusion medicine. | ||
| Line 22: | Line 23: | ||
** Precursor to A and B antigens | ** Precursor to A and B antigens | ||
* H allele frequency >99.99% | * H allele frequency >99.99% | ||
** hh is Bombay phenotype | ** hh is Bombay phenotype (O<sub>h</sub>) | ||
*** Produces anti-H antibodies | *** Produces anti-H antibodies | ||
*** Appears as Group O on T&S, but antibody screens and panels will be fully positive | |||
ABO Antigens | ABO Antigens | ||
| Line 34: | Line 36: | ||
|+ | |+ | ||
! | ! | ||
!hh | |||
!H | !H | ||
!A | !A | ||
| Line 39: | Line 42: | ||
|- | |- | ||
|Gene Product (Enzyme) | |Gene Product (Enzyme) | ||
|None | |||
|L-fucosyltransferase | |L-fucosyltransferase | ||
|N-acetylgalactosaminyltransferase | |N-acetylgalactosaminyltransferase | ||
| Line 44: | Line 48: | ||
|- | |- | ||
|Dominant/Terminal Sugar | |Dominant/Terminal Sugar | ||
|None (only precursor) | |||
|L-fucose | |L-fucose | ||
|N-acetyl-galactosamine | |N-acetyl-galactosamine | ||
| Line 49: | Line 54: | ||
|- | |- | ||
|Groups | |Groups | ||
|O<sub>h</sub> (Bombay) | |||
|A, B, AB, O | |A, B, AB, O | ||
|A, AB | |A, AB | ||
|B, AB | |B, AB | ||
|} | |} | ||
Most to least H-antigen: O > A2 > B > A2B > A1 > A1B (subgroups used for organ donation) | |||
* Most people are A1 | |||
ABO Antibodies | |||
* Develop 'naturally' regardless of exposure to blood products (may be similar to structures found in bacteria, pollen, etc.) | |||
** Non-red cell immunity | |||
* Takes time to develop (3-6 months) in infants | |||
{| class="wikitable" | |||
|+ | |||
!Blood Group | |||
!Antibodies Present | |||
!Class | |||
|- | |||
|Group A | |||
|Anti-B | |||
|IgM | |||
|- | |||
|Group B | |||
|Anti-A | |||
|IgM | |||
|- | |||
|Group AB | |||
| colspan="2" |None | |||
|- | |||
| rowspan="3" |Group O | |||
|Anti-A | |||
|IgM | |||
|- | |||
|Anti-B | |||
|IgM | |||
|- | |||
|Anti-A,B | |||
|IgG | |||
|} | |||
IgG antibodies can cross placenta, but IgM usually doesn't (except in trauma) | |||
=== Secretory Status === | |||
* A, B, and H antigens can be soluble | |||
* Se gene confers secretory status | |||
** Dominant gene (FUT-2) | |||
** Fucose added to type 1 precursor | |||
*** Type 1 precursor found in body fluids and secretions | |||
*** Type 2 precursor found on RBCs, body fluids, and secretions | |||
** H antigen is then secreted, as are any A and B antigens attached to it | |||
ABO Typing | ABO Typing | ||
* Babies: perform forward testing ONLY | * Babies: perform forward testing ONLY | ||
* Babies: if baby appears Rh Negative and the mother is Rh Negative, perform weak D testing | * Babies: if baby appears Rh Negative and the mother is Rh Negative, perform weak D testing | ||
* AB Rh Positive patients require Rh Control to be performed | * AB Rh Positive patients require Rh Control to be performed | ||
** RHC should be a '''reaction of''' '''0'''. This checks that the agglutination seen is '''not''' a result of | ** RHC should be a '''reaction of''' '''0'''. This checks that the agglutination seen is '''not''' a result of auto-agglutination in the patient. | ||
* Rh Control is also used for discrepancies (Rh testing results don't match, e.g. Anti-D1 is 2+ and Anti-D2 is 0) | * Rh Control is also used for discrepancies (Rh testing results don't match, e.g. Anti-D1 is 2+ and Anti-D2 is 0) | ||
* Rh Control is also used for IAT Testing (e.g., Weak D testing) | * Rh Control is also used for IAT Testing (e.g., Weak D testing) | ||
== Rh System == | |||
* Second most immunogenic after ABO system | |||
* RHD gene and RHCE gene | |||
** Code directly for antigens | |||
* Red cell immune, well-developed at birth | |||
** No antibodies produced unless exposed to RBCs | |||
** IgG sensitization | |||
** Anti-D can develop due to pregnancy or transfusion | |||
* Rh null is rare - no Rh antigens produced | |||
** Caused by membrane abnormalities or processing defects | |||
{| class="wikitable" | |||
!Weiner | |||
!Fisher-Race | |||
!Weiner | |||
!Fisher-Race | |||
|- | |||
|R<sup>0</sup> | |||
|Dce | |||
|r | |||
|dce | |||
|- | |||
|R<sup>1</sup> | |||
|DCe | |||
|r' | |||
|dCe | |||
|- | |||
|R<sup>2</sup> | |||
|DcE | |||
|r<nowiki>''</nowiki> | |||
|dcE | |||
|- | |||
|R<sup>z</sup> | |||
|DCE | |||
|r<sup>y</sup> | |||
|dCE | |||
|} | |||
Testing | |||
* IAT testing performed to detect IgG | |||
** Recommended to use two different reagents | |||
*** Monoclonal IgM Anti-D | |||
*** Polyclonal IgG Anti-D | |||
** Rh Control containing only diluent (e.g., bovine albumin) without anti-D | |||
*** Done to ensure there is no false agglutination (e.g., cold antibodies, etc.) | |||
Weak D Testing | |||
* Most to least D antigen: -D- > R<sup>2</sup>R<sup>2</sup> > R<sup>1</sup>R<sup>1</sup> > R<sup>1</sup>r or R<sup>0</sup>r > R<sup>1</sup>r' or R<sup>0</sup>r' | |||
* Causes: | |||
# Genetic weak D: gene codes for fewer D antigen → IAT weak-D testing | |||
# C-trans (positional) weak D: C antigen is in trans position to D antigen, blocking production of D causing weaker expression → use monoclonal anti-D | |||
# Partial D/Mosaic D: mutation causes part of Rh gene to be missing → detect by monoclonal anti-D, may need IAT weak-D testing (results may different with different antisera) | |||
#* '''Individuals can produce Anti-D to the part of the antigen that is missing - require Rh Negative blood!''' | |||
* Weak D testing not usually performed for recipients (assume patient is Rh Negative), but must be performed for donor testing | |||
** '''Weak D testing performed on all Rh Negative babies from Rh Negative moms''' to ensure baby is actually Rh Negative (if Weak D, mother could produce Anti-D) | |||
Weak D Molecular Testing | |||
* Performed for patients with special blood needs (certain prenatal patients, chronic transfusions where genotyping may modify blood products used) | |||
* Can determine whether patient has variants that can cause Anti-D production | |||
Rh and Transfusion | |||
* Rh Negative individuals may produce Anti-D when exposed to Rh Positive blood, but it is not guaranteed | |||
** Can receive Rh Positive cells at least once | |||
** Anti-D is IgG and doesn't bind complement | |||
*** Extravascular hemolysis would occur | |||
* Other Rh antigens aren't of concern unless the patient has an antibody to one or more of those antigens | |||
* Patients receiving many transfusions require special consideration (e.g., sickle cell, thalassemia, etc.) | |||
Latest revision as of 17:20, 13 February 2025
ABO System
The ABO system is the most clinically significant blood group system in transfusion medicine.
- Carbohydrate antigens
- Non-RBC stimulated: individuals possess ABO antibodies to the antigens that they lack
- IgM
- Cause severe transfusion reactions
- Cell lysis and hemolysis
ABO Genes
- A and B genes present on chromosome 9
- Code for transferase enzymes, which transfer sugar to a precursor on the RBC membrane
- A and B co-dominant, O is recessive
- One allele received from each parent
- Cis-AB inheritance
- Rare situation where A and B genes end up on same chromosome during crossover
- Can result in AB mother and OO father having AB baby
H Gene
- Present on chromosome 19
- H gene codes for a fucosyl transferase (FUT 1) that produces H antigen
- Precursor to A and B antigens
- H allele frequency >99.99%
- hh is Bombay phenotype (Oh)
- Produces anti-H antibodies
- Appears as Group O on T&S, but antibody screens and panels will be fully positive
- hh is Bombay phenotype (Oh)
ABO Antigens
- Carbohydrates attached to RBCs via gene-encoded transferase
- A and B antigens are sugars attached to terminal end of oligosaccharides
- O group has H terminal antigen instead of A or B
| hh | H | A | B | |
|---|---|---|---|---|
| Gene Product (Enzyme) | None | L-fucosyltransferase | N-acetylgalactosaminyltransferase | D-galactosyltransferase |
| Dominant/Terminal Sugar | None (only precursor) | L-fucose | N-acetyl-galactosamine | D-galactose |
| Groups | Oh (Bombay) | A, B, AB, O | A, AB | B, AB |
Most to least H-antigen: O > A2 > B > A2B > A1 > A1B (subgroups used for organ donation)
- Most people are A1
ABO Antibodies
- Develop 'naturally' regardless of exposure to blood products (may be similar to structures found in bacteria, pollen, etc.)
- Non-red cell immunity
- Takes time to develop (3-6 months) in infants
| Blood Group | Antibodies Present | Class |
|---|---|---|
| Group A | Anti-B | IgM |
| Group B | Anti-A | IgM |
| Group AB | None | |
| Group O | Anti-A | IgM |
| Anti-B | IgM | |
| Anti-A,B | IgG | |
IgG antibodies can cross placenta, but IgM usually doesn't (except in trauma)
Secretory Status
- A, B, and H antigens can be soluble
- Se gene confers secretory status
- Dominant gene (FUT-2)
- Fucose added to type 1 precursor
- Type 1 precursor found in body fluids and secretions
- Type 2 precursor found on RBCs, body fluids, and secretions
- H antigen is then secreted, as are any A and B antigens attached to it
ABO Typing
- Babies: perform forward testing ONLY
- Babies: if baby appears Rh Negative and the mother is Rh Negative, perform weak D testing
- AB Rh Positive patients require Rh Control to be performed
- RHC should be a reaction of 0. This checks that the agglutination seen is not a result of auto-agglutination in the patient.
- Rh Control is also used for discrepancies (Rh testing results don't match, e.g. Anti-D1 is 2+ and Anti-D2 is 0)
- Rh Control is also used for IAT Testing (e.g., Weak D testing)
Rh System
- Second most immunogenic after ABO system
- RHD gene and RHCE gene
- Code directly for antigens
- Red cell immune, well-developed at birth
- No antibodies produced unless exposed to RBCs
- IgG sensitization
- Anti-D can develop due to pregnancy or transfusion
- Rh null is rare - no Rh antigens produced
- Caused by membrane abnormalities or processing defects
| Weiner | Fisher-Race | Weiner | Fisher-Race |
|---|---|---|---|
| R0 | Dce | r | dce |
| R1 | DCe | r' | dCe |
| R2 | DcE | r'' | dcE |
| Rz | DCE | ry | dCE |
Testing
- IAT testing performed to detect IgG
- Recommended to use two different reagents
- Monoclonal IgM Anti-D
- Polyclonal IgG Anti-D
- Rh Control containing only diluent (e.g., bovine albumin) without anti-D
- Done to ensure there is no false agglutination (e.g., cold antibodies, etc.)
- Recommended to use two different reagents
Weak D Testing
- Most to least D antigen: -D- > R2R2 > R1R1 > R1r or R0r > R1r' or R0r'
- Causes:
- Genetic weak D: gene codes for fewer D antigen → IAT weak-D testing
- C-trans (positional) weak D: C antigen is in trans position to D antigen, blocking production of D causing weaker expression → use monoclonal anti-D
- Partial D/Mosaic D: mutation causes part of Rh gene to be missing → detect by monoclonal anti-D, may need IAT weak-D testing (results may different with different antisera)
- Individuals can produce Anti-D to the part of the antigen that is missing - require Rh Negative blood!
- Weak D testing not usually performed for recipients (assume patient is Rh Negative), but must be performed for donor testing
- Weak D testing performed on all Rh Negative babies from Rh Negative moms to ensure baby is actually Rh Negative (if Weak D, mother could produce Anti-D)
Weak D Molecular Testing
- Performed for patients with special blood needs (certain prenatal patients, chronic transfusions where genotyping may modify blood products used)
- Can determine whether patient has variants that can cause Anti-D production
Rh and Transfusion
- Rh Negative individuals may produce Anti-D when exposed to Rh Positive blood, but it is not guaranteed
- Can receive Rh Positive cells at least once
- Anti-D is IgG and doesn't bind complement
- Extravascular hemolysis would occur
- Other Rh antigens aren't of concern unless the patient has an antibody to one or more of those antigens
- Patients receiving many transfusions require special consideration (e.g., sickle cell, thalassemia, etc.)